BRISTOL-MYERS SQUIBB AND ASTRAZENECA EXPAND DIABETES ALLIANCE THROUGH BRISTOL-MYERS SQUIBB’S ACQUISITION OF AMYLIN PHARMACEUTICALS
Strengthens leadership position of successful alliance in growing area of high unmet medical need Complements current portfolio creating a more comprehensive disease management platform with the addition of novel GLP-1 franchise Adds approved and marketed products for type 2 diabetes, including BYETTAÒ and BYDUREONÒ